Regeneron to Present Late-Breaking ESMO 2026 Data on Libtayo in High-Risk CSCC and Cancer-Associated Thrombosis
Regeneron Pharmaceuticals, Inc. announced promising new clinical data at the European Society for Medical Oncology (ESMO) Congress 2026, focusing on its cancer treatment Libtayo. The presentations highlight longer-term survival outcomes for Libtayo in high-risk cutaneous squamous cell carcinoma (CSCC) and its potential as a neoadjuvant treatment for resectable CSCC. Additionally, Regeneron is exploring Factor XI inhibitors to address cancer-associated thrombosis, showcasing its commitment to comprehensive cancer care.
Argus upgrades Regeneron stock to Buy with USD 850.00 target
Argus has upgraded Regeneron stock from Hold to Buy, setting an USD 850.00 price target after the company expanded its antibody collaboration with Sanofi, securing USD 1.0 billion upfront and up to USD 7.0 billion in milestone payments. Regeneron also reported strong Q2 2026 earnings, beating analyst estimates for both EPS and revenue. The company is set to release its Q3 2026 results on October 30, 2026.
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Regeneron Pharmaceuticals announced the presentation of new clinical research at the European Society for Medical Oncology (ESMO) Congress 2026, highlighting advances in treating various cancers and associated complications. The company will share data from trials in cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC), ovarian cancer, melanoma, and cancer-associated thrombosis. Key presentations include long-term survival data for Libtayo in high-risk CSCC and exploring Factor XI inhibitors for cancer-associated thrombosis.
Pfizer (PFE) Reports Positive Phase 3 Vitiligo Results And Eyes Global Filings
Pfizer reported positive Phase 3 trial results for its oral drug LITFULO in treating nonsegmental vitiligo, showing significant clinical benefits and a favorable safety profile. The company plans to seek global regulatory approvals, including submissions to the FDA and EMA. This new indication for LITFULO, which is already approved for severe alopecia areata, will expand Pfizer's presence in immune-mediated dermatology and contributes to its strategy of shifting revenue mix toward non-COVID products.
Alector grants Genentech rights to GCase enzyme replacement therapy
Alector Inc. has granted Genentech Inc. exclusive global licensing rights for its AL-050 program, a brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy. This preclinical therapy is aimed at neurological/psychiatric conditions. The agreement allows Genentech to develop and commercialize the program worldwide.
Regeneron stock heads toward October 30 earnings after Q2 growth
Regeneron Pharmaceuticals' stock is poised for its Q3 earnings report on October 30, 2026, following a strong Q2 with 16.7% revenue growth. The company recently expanded its alliance with Sanofi, a deal valued at up to $8 billion, enhancing its pipeline. Analysts maintain a "Moderate Buy" consensus, with an average price target significantly above the current stock price.
Lakefront Biotherapeutics NV (CEUX:LKFTa) Stock Price, Trades & News
This article provides a detailed financial overview of Lakefront Biotherapeutics NV (CEUX:LKFTa), a Belgian biopharmaceutical company. It includes current stock price, market capitalization, various financial ratios (P/E, P/B, EV), and performance metrics. The company focuses on developing medicines for severe diseases and funds operations through equity financing, partnerships, and milestone-based arrangements.
How Investors Are Reacting To Regeneron Pharmaceuticals (REGN) Sanofi Alliance Expansion
Regeneron Pharmaceuticals announced early data for two new therapies and an expanded alliance with Sanofi, potentially adding up to US$8 billion in milestones. This expansion aims to diversify Regeneron's revenue beyond its current blockbusters and deepen its immunology pipeline. Investors are evaluating how this collaboration and new drug data will influence the company's long-term growth and address pressure on its existing EYLEA franchise.
Werewolf Therapeutics Inc (HOWL) Stock Price, Quote, News & History
This article provides comprehensive information on Werewolf Therapeutics Inc. (HOWL), including its stock price, key statistics, recent news, financial data, and analyst ratings. It highlights the company's biopharmaceutical focus and its recent merger with Ambros Therapeutics.
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Regeneron (REGN)
This article highlights bullish analyst ratings for two healthcare companies: Orchestra BioMed Holdings (OBIO) and Regeneron (REGN). Madison Elsaadi from B. Riley Securities reiterated a Buy rating for Orchestra BioMed with an $11.00 price target, while Salveen Richter from Goldman Sachs maintained a Buy rating for Regeneron with a $972.00 price target. Both companies are seen to have significant upside potential based on analyst consensus.
Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)
The article summarizes recent analyst ratings for three healthcare companies: TransMedics Group (TMDX), Regeneron (REGN), and Tarsus Pharmaceuticals (TARS). TransMedics Group received a "Moderate Buy" consensus with a $120.00 price target from TD Cowen and a "Buy" from William Blair. Regeneron was rated "Moderate Buy" with a $850.38 consensus price target, despite a "Hold" rating from Leerink Partners and RBC Capital. Tarsus Pharmaceuticals garnered a "Strong Buy" consensus with an average price target of $100.11, receiving "Buy" ratings from Oppenheimer and Goldman Sachs.
Regeneron Pharmaceuticals (REGN) Could Be 14% Undervalued Following $1b Sanofi Alliance Expansion
Regeneron Pharmaceuticals (REGN) recently expanded its immunology alliance with Sanofi, securing a $1 billion upfront payment and potential milestones of up to $7 billion. Despite recent share price volatility, Regeneron is considered 14% undervalued with a fair value of $850.88 compared to its closing price of $735.20. The company continues to advance a broad late-stage pipeline, but faces risks from competition for EYLEA HD and potential litigation costs.
BioLineRx Ltd (NASDAQ: BLRX) Share Price, BLRX Stock News, BLRX Share Price & Updates
This article provides an overview of BioLineRx Ltd (NASDAQ: BLRX), a commercial-stage biopharmaceutical company focused on oncology and rare diseases. It details the company's key pipeline assets, including APHEXDA for sickle cell disease, pancreatic cancer, and multiple myeloma, as well as BL-5010 for skin lesions. The piece also presents financial metrics, an AI-generated summary highlighting long-term growth potential and associated risks, and peer comparisons within the biotechnology sector.
Regeneron Pharmaceuticals, Inc. (REGN) Stock forecasts
Argus Research has upgraded Regeneron Pharmaceuticals (REGN) to a BUY rating, citing strong growth from its drug Dupixent. The biopharmaceutical company, founded in 1988, specializes in treatments for various conditions including eye diseases and cancer, and has multiple collaborations with other major pharmaceutical companies. The current price is $735.20.
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
This article compares the competitive advantages and investment potential of Vertex Pharmaceuticals (VRTX) and Regeneron Pharmaceuticals (REGN), two leading biotech companies. Vertex has built its moat through dominance in cystic fibrosis and is now expanding into other therapeutic areas, while Regeneron's strength lies in its scientific research engine that consistently produces new medicines. Despite different strategies, both companies face challenges in pipeline diversification and patent expirations, with their valuations reflecting investors' current perceptions of these moats.
Intellia Therapeutics, Inc. (NTLA) stock price, news, quote and history
Intellia Therapeutics, Inc. (NTLA) is a clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company's stock closed at $12.26 on October 2nd, with an after-hours price of $12.28, and has seen a 36.37% year-to-date return. Intellia Therapeutics is actively engaged in collaborations for developing in vivo and ex vivo therapies for various diseases, including transthyretin amyloidosis and hereditary angioedema.
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data
Regeneron Pharmaceuticals shared promising Phase 1/2 clinical trial results for ubamatamab in recurrent low-grade serous ovarian cancer, showing a 73% objective response rate. Additionally, Phase 2 COURAGE trial data for trevogrumab combined with semaglutide demonstrated muscle preservation in weight loss, with lower doses retaining significant lean mass. The company plans further studies and regulatory discussions for these therapies.
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
Sanofi and Regeneron Pharmaceuticals have expanded their long-standing antibody collaboration to include four next-generation, long-acting antibodies targeting type II inflammation, with Regeneron receiving an upfront payment of $1 billion and potential milestones up to $7 billion. The companies will co-develop and co-commercialize these antibodies, building on the success of Dupixent, which generated €9.3 billion in sales in the first half of 2026. This collaboration aims to further strengthen Sanofi's immunology portfolio and contribute to its projected €25 billion in Dupixent sales by 2030, alongside other growing medicines.
Sanofi, Regeneron broaden alliance to find their next Dupixent
Sanofi and Regeneron have expanded their long-standing alliance with a $1 billion upfront payment to develop new long-acting antibody drugs, targeting the same interleukins as their blockbuster Dupixent. This collaboration aims to create "next-generation" immunology medicines, addressing concerns about Dupixent's upcoming patent expirations and potentially setting the stage for future partnerships. While the deal is seen as positive for Regeneron, the new drugs are still in early development, and their differentiation in a crowded market remains to be proven.
Regeneron Pharma Is Maintained at Buy by Jefferies
Jefferies has reiterated its Buy rating on Regeneron Pharmaceuticals. The analyst firm continues to view Regeneron Pharma favorably, maintaining a positive outlook on the company's stock.
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
Shares of Ocular Therapeutix (OCUL) dropped significantly, heading for its worst week since April 2024, after competitors Kodiak Sciences and 4D Molecular Therapeutics released positive clinical trial updates for their longer-lasting eye injection treatments for Wet AMD. Despite this, Ocular Therapeutix still plans to file for approval of its lead drug, AXPAXLI, in Q4 2026, with analysts suggesting the current valuation is overdone given its potential sales. Retail traders remain bullish on OCUL, with some speculating about a potential buyout due to its perceived undervaluation.
Sanofi, Regeneron expand partnership after Dupixent success
Sanofi and Regeneron Pharmaceuticals have announced an expanded collaboration, building on the success of their drug Dupixent. Sanofi is providing Regeneron with $1 billion upfront and potential milestone payments up to an additional $7 billion, focusing on a new series of antibodies for immunological diseases. Regeneron will lead research and development, while Sanofi will handle commercialization, with profits split evenly.
Regeneron (REGN) Stock May Be Underpriced Despite Its $1b Alliance Expansion
Regeneron Pharmaceuticals (REGN) stock appears potentially undervalued, trading at a P/E ratio close to its sector average but below its peer group, according to Simply Wall St. This assessment comes despite a recent expansion of its alliance with Sanofi, which brings a US$1 billion upfront payment and potential milestone payments. The analysis suggests that Regeneron's current earnings multiple is at a discount to what a Fair Ratio benchmark indicates, factoring in the company's margins, growth profile, size, and risk.
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
This article identifies three top gene therapy stocks—Vertex Pharmaceuticals (VRTX), Exelixis (EXEL), and Regeneron Pharmaceuticals (REGN)—that balance high upside potential with financial discipline, appealing to investors seeking growth in the biotechnology sector amidst rising borrowing costs. It highlights their revenue streams, market values, and specific treatments, while also addressing potential risks and future growth drivers for each company. The article emphasizes that these selections are part of a broader screener for biotech firms with compelling narratives.
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
Ocular Therapeutix (OCUL) stock is experiencing its worst week in 2.5 years following positive clinical trial updates from rivals Kodiak Sciences and 4D Molecular Therapeutics for wet age-related macular degeneration (Wet AMD) treatments. While competitors demonstrated advancements in longer-lasting eye injections and gene therapy, Ocular Therapeutix still plans to file for approval of its lead drug, AXPAXLI, in Q4 2026. Despite the stock drop, analysts believe the valuation is undervalued given the drug's potential, and retail sentiment remains "extremely bullish."
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00
Jefferies Financial Group raised its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) to $930.00 from $870.00, maintaining a "buy" rating, indicating a potential upside of 25.63%. The biopharmaceutical company recently reported strong quarterly results, exceeding EPS and revenue expectations. Regeneron's outlook is further bolstered by an expanded alliance with Sanofi and promising early-stage data from its obesity and cancer pipeline programs.
Regeneron posts trial data for ovarian cancer therapy (REGN:NASDAQ)
Regeneron Pharmaceuticals (REGN) shares dropped after the company reported initial results from a Phase 1/2 trial for ubamatamab, an experimental therapy for ovarian cancer. This decline occurred despite earlier gains from an expanded collaboration with its partner Sanofi (SNY).
Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion
Sanofi and Regeneron Pharmaceuticals are expanding their two-decade-long antibody development partnership, with Sanofi pledging up to $8 billion. This expanded agreement builds on the success of their jointly developed drug Dupixent and aims to co-develop four new long-acting antibodies. Sanofi will make a $1 billion upfront payment to Regeneron, with potential for an additional $7 billion in milestone payments, and both companies will equally share development costs and future profits for the new programs.
Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent
Sanofi and Regeneron have expanded their R&D alliance, with Sanofi investing $1 billion to develop four next-generation antibody drugs intended to succeed their blockbuster immunology drug, Dupixent. These new therapies, stemming from the same Regeneron platform that produced Dupixent, are projected to reach pivotal testing around 2029, strategically timed before Dupixent's patent expiration in 2031. The agreement also settles prior litigation between the companies regarding Dupixent's commercialization.
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Sanofi and Regeneron have expanded their DUPIXENT alliance in a deal potentially worth up to €8 billion, focusing on next-generation medicines for type 2 inflammatory diseases. Sanofi will provide an upfront payment of €1 billion and up to €7 billion in milestones, while the companies will share development costs and global profits equally. The collaboration includes four new antibody programs, with the lead asset targeting a long-acting IL-13 antibody for atopic dermatitis, aiming for a less frequent dosing schedule.
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
Sanofi and Regeneron have renewed their partnership, with Sanofi providing $1 billion upfront and up to $7 billion in milestones, to develop next-generation antibodies for immune-mediated conditions. This agreement aims to find a successor to their blockbuster drug Dupixent, which faces patent expiry in 2031, despite a history of disputes between the companies. The collaboration includes four new therapies, led by REGN20423 in Phase 1 for atopic dermatitis, and could potentially integrate Sanofi's TSLPxIL-13 bispecific lunsekimig into the alliance.
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus
Argus has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) to a "buy" rating with an $850 price target, signaling a potential upside of 12.1% from its previous close. The company recently surpassed quarterly expectations, reporting strong adjusted EPS and revenue growth. Regeneron's strategic partnerships and pipeline developments, including an expanded alliance with Sanofi and promising weight-loss combination data, contribute to its growth potential despite increasing competition for its drug Eylea.
Cantor Fitzgerald reiterates Dyne Therapeutics stock rating
Cantor Fitzgerald reiterated an Overweight rating on Dyne Therapeutics (NASDAQ:DYN) after the biotech company released additional one-year data from its Phase 1/2 ACHIEVE study for DM1 patients. Despite a 17% year-to-date stock decline, shares are up 28% over the past year. The company's financial position is strong, with more cash than debt, as it progresses towards regulatory milestones, though some analysts have adjusted price targets due to Novartis's recent trial failure in a similar study.
Sanofi forges new $8bn pact with Regeneron
Sanofi and Regeneron have expanded their long-standing R&D alliance with a new pact worth up to $8 billion, focusing on four new immunology and inflammation medicines. This collaboration builds on their success with Dupixent and aims to develop next-generation therapies for immune-mediated diseases. The deal includes a $1 billion upfront payment to Regeneron, with potential for an additional $7 billion if the drugs succeed.
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
Sanofi and Regeneron have expanded their long-standing immunology partnership in a deal that could reach $8 billion. This collaboration will focus on co-developing and co-commercializing four new long-acting antibodies. The move aims to bolster their immunology pipeline following the success of Dupixent and address investor concerns about its patent expiry in 2031.
Jefferies Raises Regeneron Pharmaceuticals Price Target to $930 From $870
Jefferies has raised its price target for Regeneron Pharmaceuticals (REGN) to $930 from $870. The stock currently has an average rating of "overweight" and a mean price target of $855.7. This news comes from MT Newswires.
B.Riley reiterates Kymera Therapeutics stock rating on new trial data
B.Riley has reiterated a Buy rating and a $155.00 price target for Kymera Therapeutics (NASDAQ: KYMR) after the company presented new data from its oral STAT6 degrader KT-621 at EADV’26. The stock has seen a 104% increase over the past year, reflecting strong investor interest. Several other analysts, including Stifel, BofA Securities, Guggenheim, and Piper Sandler, have also recently increased their price targets and maintained Buy or Overweight ratings, indicating broad positive sentiment driven by potential Phase 2b data for KT-621.
Pfizer’s Phase II Atopic Dermatitis Data Push Tilrekimig Into Pivotal AD, Asthma Trials
Pfizer is advancing its trispecific drug, tilrekimig, into pivotal Phase III trials for atopic dermatitis and asthma, following positive Phase II data. The company is also conducting a Phase IIb/III study for tilrekimig in COPD, aiming to assess the efficacy of targeting three pathways simultaneously. This move signifies Pfizer's renewed efforts in the atopic dermatitis space and its broader strategy for immune and respiratory disorders.
Regeneron drug said to cut muscle loss when combined with Novo's semaglutide (REGN:NASDAQ)
An experimental weight-loss drug from Regeneron, when combined with Novo Nordisk's semaglutide, reportedly reduced muscle mass loss by 50% compared to semaglutide alone. This finding comes from a study involving patients, suggesting a potential improvement in weight-loss treatment outcomes by mitigating adverse effects like muscle wasting.
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
Sanofi and Regeneron Pharmaceuticals have announced an agreement to expand their alliance for the joint development and commercialization of new immunology drugs. The deal could be worth up to $8 billion for Regeneron, including a $1 billion upfront payment from Sanofi and up to $7 billion contingent on development, regulatory, and commercial milestones. The companies will equally share costs and future profits from these new drugs.
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
French drugmaker Sanofi will pay its U.S. partner Regeneron $1 billion upfront and up to an additional $7 billion in milestone payments to expand their immunology partnership. This deal adds four new long-acting immunology antibodies to their collaboration, which already includes the blockbuster eczema drug Dupixent. The companies have also settled previous litigation and will share costs and profits equally for the expanded venture, with Regeneron leading R&D and Sanofi handling global sales.
Sanofi, Regeneron Seal Deeper Partnership Worth Up to $8 Billion
Sanofi and Regeneron Pharmaceuticals have expanded their partnership with a new deal potentially worth up to $8 billion for the U.S. drugmaker. This alliance will focus on co-developing and co-commercializing four new antibody drugs targeting immune system-related diseases. The announcement was made on Thursday by both companies.
Regeneron and Sanofi Expand Long-Standing Collaboration to Add Next-Generation Long-Acting Immunology Antibodies in Deal Worth Up to $8 Billion
Regeneron Pharmaceuticals and Sanofi have expanded their collaboration to include four new long-acting immunology antibodies, building on their successful partnership that developed Dupixent. Regeneron will receive an upfront payment of $1 billion, with potential milestone payments of up to an additional $7 billion, and both companies will share development costs and profits equally. This expansion aims to accelerate the development of innovative therapies for immune-mediated conditions, with the new antibodies expected to enter clinical studies in 2027.
Four antibodies join a deal that pays Regeneron $1 billion upfront, with up to $7 billion more possible.
Regeneron has expanded its antibody alliance with Sanofi, securing a $1 billion upfront payment and potential additional milestone payments of up to $7 billion. This expanded collaboration adds four new long-acting antibodies to their joint development efforts, with costs and future global profits to be split equally. The agreement also includes an option for Regeneron to add Sanofi’s investigational lunsekimig after its Phase 3 trials for chronic obstructive pulmonary disease.
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
Sanofi is investing $1 billion upfront with potential milestones up to $7 billion in a new collaboration with Regeneron for four early-stage immunology programs. This partnership aims to replicate the success of their blockbuster drug Dupixent, whose patent expires in 2031, by developing next-generation assets. The deal also serves to mend a previously strained relationship between the two pharmaceutical giants.
Regeneron’s ALN-F1202 Safety Trial Marks a Quiet but Important Pipeline Milestone
Regeneron Pharmaceuticals (REGN) has completed a Phase 1 study for ALN-F1202, an experimental drug designed to block Factor XII, a protein involved in blood clotting and inflammation. This randomized, double-blind, placebo-controlled trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of ALN-F1202 in healthy adults. The completion and recent update of this safety trial suggest Regeneron is preparing for potential Phase 2 programs, offering a quiet but important milestone for investors tracking the company's pipeline beyond its established franchises.
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
Kodiak Sciences saw its stock triple overnight after its eye drug, Zenkuda, met primary goals in a pivotal Phase 3 trial for wet age-related macular degeneration. Despite this success, the company faces challenges including significant cash burn, a shrinking cash balance, and the likelihood of a dilutive share offering. The article questions whether Zenkuda can compete against cheaper Eylea biosimilars and emphasizes that its commercial viability hinges on its reduced injection frequency.
The 18th investor summit will be held at San Francisco's St. Regis, with Cohu management taking part.
Cohu, Inc. (NASDAQ: COHU) announced its management will participate in the 18th Annual CEO Investor Summit on October 13, 2026, at the St. Regis Hotel in San Francisco. The summit features a "round-robin" format of small group meetings with company management and is by invitation only for accredited investors and publishing research analysts. Presentation materials will be available on Cohu's investor website.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Average Target Price of $802.18
Regeneron Pharmaceuticals (NASDAQ:REGN) has received a "Moderate Buy" consensus rating from 24 analysts, with an average 12-month price target of $802.18. The company recently surpassed quarterly earnings and revenue expectations, but faces potential competition in its Eylea franchise. Insider selling has been observed, while institutional investors hold a significant portion of the shares.
Valneva SE (OTC: INRLF) Stock Price, News & Analysis
Valneva SE (OTC: INRLF) is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases. The company offers vaccines like IXIARO and DUKORAL, and has a pipeline including candidates for Lyme disease, chikungunya, and Zika virus. Financial data and peer comparisons are provided, highlighting the company's revenue, net income, and market capitalization, along with an AI summary of its growth potential and inherent risks.
